Changes in company's own shares

Rhea-AI Summary

Alvotech (ALVO) filed a notification with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) on 29 Dec 2025 regarding changes in the company's own shares. An attachment titled Alvotech Own Shares Notification 29 Dec 2025 was submitted with the filing. Investors should review the attached notification for the specific details and scope of the share changes.

Key Figures

CSSF filing date 29 Dec 2025 Own-share notification filing attachment date

Market Reality Check

$4.97 Last Close

Volume Volume 360,929 is below the 20-day average of 644,244 ahead of this own-share filing. low

Technical Shares at $5.26 are trading below the 200-day MA of $8.3, well under the 52-week high of $13.7.

Peers on Argus

Peers show mixed, modest moves: SUPN -0.39%, BHC +0.35%, ANIP +0.61%, HCM -0.79%, INDV +0.11%, suggesting today’s action is stock-specific.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 22	Financial calendar	Neutral	+0.8%	Publication of 2026 financial calendar and key reporting dates.
Dec 22	Product launch	Positive	+0.8%	European launch of first-in-market Simponi biosimilar Gobivaz with Advanz.
Dec 19	Settlement/license deal	Positive	+3.6%	Settlement granting AVT06 U.S. marketing start in Q4 2026, if approved.
Dec 17	Convertible placement	Negative	-0.8%	USD 108M senior unsecured convertible bonds due 2030 in oversubscribed deal.
Dec 16	Convertible offering	Negative	-6.7%	Launch of USD 100M convertible bond plus 2025/2026 revenue and EBITDA guidance.

Pattern Detected

Recent news has generally moved ALVO in the same direction as the perceived news tone, with negative reactions around financing/offering announcements.

Recent Company History

Over recent months, Alvotech has reported multiple regulatory and financing milestones. In December 2025, it launched a Simponi biosimilar in Europe and secured a U.S. settlement for AVT06, both followed by positive price reactions. Convertible bond and offering announcements in mid‑December 2025 drew negative reactions, consistent with dilution concerns. Earlier 6-K filings through November 2025 highlighted EEA approvals and EMA review progress. Today’s CSSF own-share filing fits into an active period of capital and regulatory activity rather than a new strategic shift.

Market Pulse Summary

This announcement references a CSSF filing on changes in the company’s own shares, highlighting governance and capital-structure transparency rather than operational developments. It comes after an active period of regulatory progress, financings, and detailed guidance for 2025–2026. With the stock trading below its 200-day MA of $8.3 and well under the $13.7 52-week high, investors may focus on the filing’s specifics alongside upcoming earnings dates and the execution of recent bond and biosimilar launch plans.

AI-generated analysis. Not financial advice.

Attached is a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding changes in company's own shares.

Attachment

• Alvotech Own Shares Notification 29 Dec 2025

FAQ

What did Alvotech (ALVO) announce in the CSSF filing on December 29, 2025?

Alvotech submitted a notification to the CSSF reporting changes in the company's own shares with an attachment named Alvotech Own Shares Notification 29 Dec 2025.

Where was Alvotech's (ALVO) own shares notification filed on December 29, 2025?

The notification was filed with the Luxembourg regulator, the Commission de Surveillance du Secteur Financier (CSSF).

How can investors see the details of Alvotech's (ALVO) own shares change on December 29, 2025?

Investors should review the attached document titled Alvotech Own Shares Notification 29 Dec 2025 included with the CSSF filing for the specific details.

Does the December 29, 2025 CSSF filing for Alvotech (ALVO) state the number or value of shares changed?

The brief notice identifies a filing about changes in own shares but does not specify numbers or values; those details would be in the attached notification.

What immediate investor actions are suggested after Alvotech's (ALVO) own shares notification on December 29, 2025?

Review the attached notification for specifics, monitor company filings and investor relations, and consider contacting investor relations for clarification.